Initial Board Composition. Effective as of immediately after the Effective Time the Board (the “Initial Board”) shall comprise: (a) three directors designated by Sumitovant Bio as Sumitomo Directors, who shall be ▇▇▇▇▇▇ ▇▇▇▇▇▇ (who shall serve as the Chairman of the Board), ▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇▇▇ ▇▇▇▇▇▇; (b) three Independent Directors, who shall be ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇ and ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ (who shall serve as Lead Independent Director) (the “Initial Independent Directors”); and (c) the Principal Executive Officer of the Company.
Appears in 2 contracts
Sources: Investor Rights Agreement (Myovant Sciences Ltd.), Investor Rights Agreement (Sumitomo Chemical Co., Ltd.)